menu

Investigating the Next Generation of CDK2/4/6 Inhibitors: Insights from the 2021 SABCS

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Investigating the Next Generation of CDK2/4/6 Inhibitors: Insights from the 2021 SABCS

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    With a lack of clear standards of care in the post CDK4/6 inhibitor setting, a new study aims to address this unmet need. Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares clinical trial data and its impact on cancer patients.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    With a lack of clear standards of care in the post CDK4/6 inhibitor setting, a new study aims to address this unmet need. Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares clinical trial data and its impact on cancer patients.

Facebook Comments

Schedule1 Oct 2022
Webpack App